Navigation Links
Arpida Completes Enrolment in Phase II "Intravenous-to-Oral" Switch Trial With Oral Iclaprim
Date:9/24/2008

REINACH, Switzerland, September 24 /PRNewswire-FirstCall/ -- Arpida Ltd. (SWX: ARPN) today announced the completion of enrolment in the Phase II 'intravenous-to-oral' switch trial with oral iclaprim in patients with complicated Skin and Skin Structure Infections (cSSSI).

The trial was designed as a multi-centre, double-blind comparative study. Patients suffering from cSSSI received intravenous (IV) vancomycin for the first two days of treatment and were then randomised to either continue to receive IV vancomycin or to be switched to oral iclaprim for eight additional days. A total of 60 patients have been randomised for this study.

The key objective of the study is to assess the clinical efficacy of an oral capsule formulation of iclaprim as step-down therapy in comparison with IV vancomycin in the treatment of cSSSI. The primary endpoint is the clinical cure rate at the Test-of-Cure (TOC) visit. Secondary objectives include bacteriological outcome as well as safety and tolerability.

Dr Paul Hadvary, Head of Development of Arpida Ltd., commented: "The speed of enrolment in this Phase II trial surpassed our expectations. It again shows that an 'intravenous-to-oral' step-down therapy serves a medical need and could add significant value to intravenous iclaprim. Marketing applications for intravenous iclaprim have been filed in the U.S.A., the European Union and Canada. We will release the top-line data of this Phase II switch study in the coming months and subsequently determine the path ahead."

About Arpida Ltd.

Arpida (SWX: ARPN) is a biopharmaceutical company headquartered in Reinach, Switzerland with operations in Switzerland and the USA. It focuses on the discovery, development and commercialisation of novel drugs that seek to overcome the growing problem of microbial resistance. The most advanced compounds include an antibacterial under regulatory review and an antifungal in Phase III.

Arpida's leading product can
'/>"/>

SOURCE Arpida Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Arpida Invited to Present Data on Iclaprim at Scientific Conference
2. Arpida Provides Further Comments on the Pivotal Phase III Trials
3. Arpida Enrols First Patients in "Intravenous-to-Oral" Switch Trial With Oral Iclaprim
4. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
7. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
8. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
9. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
10. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
11. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 17, 2014 With advancements in neurological ... market is seeing new growth, according to Kalorama ... account for the majority of market volume, newer ... images, which are creating opportunities for more sophisticated applications. ... growing at a rate of 4%, with world ...
(Date:12/17/2014)...  IGI Laboratories, Inc. (NYSE MKT: IG; "IGI" or ... of $125 million aggregate principal amount of 3.75% Convertible ... offered and sold only to qualified institutional buyers pursuant ... as amended (the "Securities Act"). The Notes ... year, payable semiannually in arrears on June 15 and ...
(Date:12/15/2014)... 15, 2014 Registreer nu via  ... und 20. Februar sind alle akkreditierten pharmazeutischen ... ECOSYSTEM PARTNER PROGRAMM ™ 2015 in ... Diese Tagung soll dazu beitragen, der ... die neue profitablen Unternehmensdienstleistungen, die für Apotheken ...
Breaking Medicine Technology:Kalorama: 3T Advancements Bringing New Growth to the MRI Market 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 2IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 4Symposium über Aegates Ecosystem-Partner-Programm für sichere Medikamente vom 19. - 20. Februar 2015 in Amsterdam 2
... implement advanced patient outcome analysis software to monitor health ... Global Health Research Foundation (GHRF) today ... the Westly Foundation to fund asthma treatment in California,s ... asthma cases in the state. The grant will help ...
... February 4 Oramed,Pharmaceuticals, Inc. (OTCBB: ORMP.OB), a ... it has concluded a proof of concept,study in ... technology. Eight healthy volunteers came for two visits, ... The insulin suppositories showed rapid insulin absorption and ...
Cached Medicine Technology:Global Health Research Foundation Awarded $25,000 Grant From Westly Foundation to Study Asthma in California's Central Valley 2Oramed Pharmaceuticals Completes Proof of Concept Study of Insulin Suppository 2
(Date:12/17/2014)... A group of 127 scientists sent an ... reaction to a recent statement by the center that was ... derogated the efficacy of all brain exercises. , Signatories to ... of the center’s statement critical of brain exercise companies that ... overstated its case, in a document it had entitled “A ...
(Date:12/17/2014)... 2014 (HealthDay News) -- As gas prices rose in ... new study suggests. In times of gas increases, ... riders are inexperienced, the researchers explained. They examined ... has the highest number of motorcycle registrations in the ... deaths. The analysis revealed a strong association between ...
(Date:12/17/2014)... HealthDay Reporter TUESDAY, Dec. ... fast approaching, a new study reveals that states that routinely ... drunk drivers on their roads. The finding suggests that ... able to deter inebriated revelers from getting behind the wheel ... being passed regarding drinking and driving," said study lead author ...
(Date:12/15/2014)... CITY, NV (PRWEB) December 15, 2014 ... powerhouse company, JM Ocean Avenue. JM Ocean Avenue ... of the Veretekk online automated marketing system. JM ... the June 2014 merger of Ocean Avenue and JM ... more than $2 Billion per year company. , “After ...
(Date:12/15/2014)... December 15, 2014 Health Dialog, ... announced today that it has received Patient Oriented ... (NCQA) for its Disease Management (DM) Programs for ... (COPD), coronary heart disease and diabetes. This marks ... for Health Dialog’s Disease Management (DM) Programs, reaffirming ...
Breaking Medicine News(10 mins):Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 3Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 4Health News:When Gas Prices Go Up, So Do Motorcycle Accidents, Study Finds 2Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 2Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 2Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 4Health News:Health Dialog Receives NCQA Accreditation for Disease Management Programs 2
... leader in,providing do-it-yourself market research, and Funky Monkey ... released the,results of a client sponsored online survey ... their recommended daily dose of fruit., According ... consumption,include spoilage (47%), need for preparation (28%), stickiness ...
... MATEO, Calif., Dec. 5 BioForm Medical,Inc. (Nasdaq: ... it will,report its September 30, 2007 first quarter fiscal ... press release after the NASDAQ,Global Market closes and will ... Time (5:30 p.m. Eastern Time)., BioForm Chief Executive ...
... on http://www.thepill.com , RARITAN, N.J., Dec. 5 ... do Modern Girls really know about this birth,control choice?, ... http://www.prnewswire.com/mnr/ortho/29291/ , Since its development more than 45 years ... control method. Although more than 80 percent,of American women have ...
... Donates "Asthma & Allergy Friendly" Toys to Kids ... Dec. 5 The oldest and largest,allergy patient ... Allergy,Foundation of America (AAFA), made the holidays a ... to asthma, allergies or,other respiratory diseases by donating ...
... media attention, bi-coastal ... distribution underway, PORTLAND, Maine, Dec. ... new line of all-natural simmer sauces for,chicken. The new sauces -- ... Foods markets throughout the north Atlantic (MA,ME, RI) and northeast regions ...
... HSKA ) today announced it will present at the ... Conference on,December 11, 2007 at 1177 Avenue of the ... York, NY. The presentation is scheduled to begin,at 2:10 ... be available,via live webcast and for two weeks following ...
Cached Medicine News:Health News:Why Fruit Gets Short Shrift in U.S. Diet: Online Poll 2Health News:BioForm to Announce First Quarter Fiscal 2008 Financial Results and Host Conference Call and Webcast on December 13, 2007 2Health News:Video: What 'Modern Girls' Should Know About the Pill 2Health News:Video: What 'Modern Girls' Should Know About the Pill 3Health News:Allergy Foundation Thinks Globally, Gifts Locally 2Health News:Good Clean Food's New Line of All-Natural Simmer Sauces for Chicken Hits Market Shelves 2Health News:Good Clean Food's New Line of All-Natural Simmer Sauces for Chicken Hits Market Shelves 3
... a medical device designed to handle the ... and archiving demands of the EEG laboratory. ... that helps organize workflow and the collection, ... database and powerful search capability keeps track ...
... The P3000 heralds a new concept in pupillometry, ... infrared optical system developed for the P2000. ... in which we have paid particular attention to ... Our new system is extremely flexible, allowing you ...
...
... Peg electrodes typically are ... to enable epidural recording of ... contacts and are furnished in ... skull thicknesses. A 4.6 mm ...
Medicine Products: